A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project

To the Editor,

ZIP7 deficiency is the most recently described congenital agammaglobulinemia with autosomal recessive inheritance. ZIP7, encoded by SLC39A7, is an endoplasmic reticulum-to-cytoplasm Zn2+ transporter. Developing B cells are sensitive to altered Zn2+ distribution, which causes developmental blockade beyond the pre-B cell stage. Complete loss of ZIP7 in cell lines causes a reduction in cytoplasmic Zn2+ and an increase in endoplasmic reticulum Zn2+ concentration. Since the original report in 2019, no additional cases of ZIP7 deficiency have been published. Here, we describe a patient evaluated for recurrent respiratory tract infections, meningitis, agammaglobulinemia, and B cell lymphopenia, ultimately found to carry a novel SLC39A7 variant. We describe his clinical characteristics, immunological findings, and genetic investigations. We also report on the impact of the J Project (JP) in improving primary immunodeficiency (PID) patient care and research in Eastern and Central Europe (ECE).

The patient and his family members were interviewed, examined, treated, and monitored at the University Clinic for Children’s Disease in Skopje. Medical records were obtained from the electronic registry of the University Clinic. The mother of the patient has given written informed consent to conduct the study and for the publication of data. All procedures were performed in accordance with the ethical standards of the Institutional Research Committee. Genomic DNA from the patient and his family members was isolated with the Gen Elute Blood Genomic DNA kit (Sigma-Aldrich) and subjected to whole-exome sequencing (WES) in the patient and targeted gene sequencing in the patient and available family members. WES was performed at the New York Genome Center and the Rockefeller University using an Illumina HiSeq 2500 sequencing system (Illumina). Exome capture was carried out with SureSelect human all exome kit (Agilent) in accordance with the manufacturer’s instructions. Putative disease alleles found by WES were validated by dideoxy Sanger sequencing in the patient AND in family members. Exons and flanking intronic regions of SLC39A7 were amplified by PCR. Amplicons were sequenced with the Big Dye Terminator cycle sequencing kit (Applied Biosystems), and targeted regions were analyzed by an ABI 3130 capillary sequencer (Applied Biosystems). Sequence variants were determined by comparing with the appropriate GenBank reference sequence to identify the position of mutations.

The patient, a 14-year-old boy, and the third child in a Macedonian family of Albanian origin was born at term. Birth weight and length were in the normal ranges, and neonatal adaptation was uneventful. Consanguinity in the family was not reported. The patient received only BCG vaccination at birth indicated by a small scar on the left shoulder. Major clinical manifestations are shown in Figure 1. Treatment with ceftriaxone, 50 mg/kg/day for 10 days, resulted in the clinical and radiological recovery of pneumonia at 4 years of age. He was suspected of immunodeficiency, but the family failed to meet the medical appointments for immunological evaluation. At 7 years of age, he developed meningitis, but pathogenic microorganisms did not cause infection.

FIGURE 1 Clinical manifestation, age, and diagnostic procedures

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2022 The Authors. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
TABLE 1  Clinical and laboratory data of patients with SLC39A7 mutation

| Feature/Patient                | P1  | P2  | P3  | P4  | P5  | P6  | Our patient |
|-------------------------------|-----|-----|-----|-----|-----|-----|-------------|
| ZIP variants                  | P190A | E363K | L217P | E451X | T395I | P190A | T351A |
| **Clinical data**             |     |     |     |     |     |     |             |
| Age at first manifestation    | <1  | <1  | 12  | 23  | <1  | 26  | 6           |
| (m)                           |     |     |     |     |     |     |             |
| Age at diagnosis of           | 0.1 | 0   | 14  | 8   | 3   | 6   | 9.5         |
| agammaglobulinemia (yr)       |     |     |     |     |     |     |             |
| Age at description (yr)       | 5.5 | 3.5 | 32  | 16  | 11  | 18  | 14          |
| Gender                        | M   | M   | F   | F   | F   | F   | M           |
| Ethnic origin                 | N European | N European | N European | S Asian | Hispanic | N European | S-E European |
| Consanguinity                 | No  | no  | no  | no  | no  | no  | no          |
| Bacterial infections          | Yes | yes | yes | yes | yes | yes | yes         |
| Upper and lower respiratory  | NA  | NA  | NA  | NA  | NA  | NA  | yes (since 6 m) |
| tract infections (age)        |     |     |     |     |     |     |             |
| Skin rash                     | NA  | NA  | NA  | NA  | NA  | NA  | yes (9 yr)  |
| Other clinical diseases       |     |     |     |     |     |     |             |
| (especially liver diseases)   |     |     |     |     |     |     |             |
| Treatment                     | HSCT | HSCT | IVIG | IVIG | IVIG | SCIG | IVIGc       |
| Height (cm) [centile] at      | 101.1 [3rd] | 85 [3rd] | 160 [40th] | 152 [5th] | 140 [25th] | 173 [90th] | 149 [<5]   |
| description                   |     |     |     |     |     |     |             |
| Weight (kg) [centile] at      | 16.3 [10th] | 13.4 [10th] | 60 [50th] | 38 [<0.4th] | 27 [50th] | 71 [73rd] | 29.6 [<1] |
| description                   |     |     |     |     |     |     |             |
| **Immunoglobulins**           |     |     |     |     |     |     |             |
| IgG (g/L)                     | 1   | 30.1b | 0.14 | 4.58§ | <1.4 | <1.7 | <3.2        |
| IgA (g/L)                     | 0.25 | 0.16a | <0.06 | <0.06 | 0.17a | <0.07 | <0.25       |
| IgM (g/L)                     | <0.22 | 0.19a | <0.04 | <0.04 | 0.23a | 0.09 | <0.32       |
| **Lymphocyte subsets**        |     |     |     |     |     |     |             |
| CD3+ (/ul)                    | 9036 | 1308 | NA  | 1121 | 94.5% | 6180 | 2586 (700 – 2200) |
| CD4+ T cell (/ul) (norm)      | 8031 | 1031 | NA  | 566  | 61.1% | 4141 | 789 (450 – 1400) |
not yield from the cerebrospinal fluid, which could be due to the previously started cephalosporin antibiotic therapy. After two weeks of treatment with 3rd generation intravenous cephalosporin, he was discharged from the hospital but continued to develop recurrent upper respiratory tract infections treated mostly by the family pediatrician. At the age of 9 years, he developed pneumonia, and received intravenous antibiotics, inhalative Colistin (polymyxin E), developed pneumonia and antimycotic treatment because C. albicans was also isolated from the tracheal aspirate. Multiple rigid bronchoscopic lavages were also performed as part of the treatment. The family history was negative for primary immunodeficiencies and hematological disorders. His mother and three siblings (2 boys and 1 girl) are healthy; his father died in a car accident at the age of 33 years.

The total number of white blood cells, red blood cells, and platelets was normal, but the patient had hypochromic anemia, neutropenia, and CD19+ B cell lymphopenia (Table 1). The CD8+ T cell count was high resulting in an inverted CD4+/CD8+ ratio, but the CD4+ cell number was normal and the HIV PCR test was negative. Immunochemistry tests revealed agammaglobulinemia, and the absence of pathogen-specific antibodies to tetanus toxoid, H. influenza type B, and Str. Pneumoniae (Table 1). Concentrations of complement components C3 and C4 were normal, and the measurement of thyroid hormones showed normal levels of fT3 and fT4. The Quantiferon-TB test was negative.

Based on these findings, monthly intravenous immunoglobulin (IVIG) therapy was started (Figure 1). Inborn errors of immunity (IEI)-related genes were analyzed based on the most recent updated classification of the International Union of Immunological Societies Expert Committee.4 Mutation screening by WES revealed that the patient harbored a private homozygous variant in SLC39A7. The variant was predicted to be deleterious (CADD score: 27.1).No other disease-causing variants in other IEI-related genes were identified by WES. The SLC39A7 sequence variant was validated by targeted gene sequencing, and we found that the patient was homozygous, whereas his mother and three siblings were all heterozygous (Table 2). We have also checked the WES files for other homozygous regions and found that the consanguinity % was below 1% (0.18105%) suggesting that this patient was not from a consanguineous marriage.5

Similar to defects of B cell development to rearrange heavy and then light chain immunoglobulin genes that lead to AR and X-linked agammaglobulinemias, loss of function alleles of SLC39A7 may lead to impaired B cell signaling.6 The patient described in this report had agammaglobulinemia, lack of B cells, and hypoplastic lymph nodes and tonsils despite recurrent upper respiratory tract infections. We thought of XLA and searched for BTK mutation first but found wild-type sequences in the patient (not shown). Next, WES and targeted gene sequencing were used to search for known AR and AD agammaglobulinemia genes, and we found in the patient’s DNA a previously unknown c.1051A>G, p. Thr351Ala SLC39A7 mutation. By using blood-derived DNA samples from all available family members, we confirmed homozygosity of this SLC39A7 mutation in the patient.
FIGURE 2 Homozygous SLC39A7 mutation in a patient with autosomal recessive agammaglobulinemia. (A) Family Pedigree with SLC39A7 allele segregation. The black-filled symbol indicates the proband (P) having the novel homozygous SLC39A7 mutation. Symbols consisting of black and white colors indicate heterozygous disease carriers as determined by targeted sequencing. Diagonal bar indicates a diseased individual. Generations are designated by a Roman numeral (I and II), and each individual by an Arabic numeral (from left to right). DNA was obtained for genetic analysis from all individuals to whom a number is assigned. Automated sequencing profiles show homozygous c.1051A>G, p.T351A mutation in the proband (II.3; P) and heterozygous mutations in four family members (I.2, II.1, II.2, II.4). C—Control. (B) Schematic representation of domain structure of ZIP7 and localization of mutations. Numbers above and below the scheme indicate the amino acid residue numbers. Numbers below the scheme show the borders of histidine-rich domains. Positions of the identified SLC39A7 variants including six missense (P190A, L217P, T351A, E363K, T395I, and G458A) and two nonsense (Q372X and E451X) mutations. The novel T351A mutation is marked in red. Mutations in bold were observed in homozygous form. TM—transmembrane; His—histidine

TABLE 2 Molecular genetic testing of disease-causing genes in 316 samples from patients in 15 J Project countries

| Gene symbols | Countries | AID | AIRE | ARP | C1B | BTK | C2 | CD40L | CXC R4 | CYBB | DKC1 | DOCK8 | ELANE | FASG | FOXP3 | G6PC3 | IKBKG | IL2RG | JAGN1 |
|--------------|-----------|-----|------|-----|-----|-----|----|-------|--------|------|------|-------|-------|------|-------|-------|-------|-------|-------|
|              |           |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 1. Azerbaijan |           |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 2. Croatia    | 2         |     | 1    |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 3. Czechia    |           |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 4. Hungary    | 6 12 1 18 2 17 1 7 1 2 6 3 1 1 5 4 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 5. Latvia     | 6 12 1 18 2 17 1 7 1 2 6 3 1 1 5 4 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 6. Moldova    | 1         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 7. Macedonia  | 1         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 8. Poland     | 7         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 9. Romania    | 1 1 9 2 3 4 2 1 1 1 1 1 1 1 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 10. Russia    | 1 11 2 4 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 11. Serbia    | 1         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 12. Slovakia  | 1         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 13. Slovenia  | 2         |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 14. Turkey    |           |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| 15. Ukraine   | 2 28 2 3 1 1 1 1 1 1 1 1 1 1 1 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
| SUM          | 8 16 1 80 2 26 9 20 3 2 8 5 1 1 1 1 8 4 |     |      |     |     |     |    |       |        |      |      |       |        |      |       |        |       |       |       |
and heterozygosity in family members who were clinically healthy (Figure 2). The gene encoding the zinc transporter protein ZIP7 has been implicated to cause autosomal recessive agammaglobulinemia in white European, South Asian, and Hispanic ancestries. To our knowledge, the patient reported here is the first diagnosed with inherited ZIP7 deficiency in Central and Eastern Europe.

Hematologic stem cell transplantation (HSCT) was found beneficial in two of the six patients in the previous study; these two patients had the most severe disease phenotype including failure to thrive, blistering dermatitis, and thrombocytopenia in addition to early-onset infections, agammaglobulinemia, and B cell depletion, which were present in all patients (Table 1). The other four patients, including those two with failure to thrive, liver dysfunction, and seborrheic dermatitis, responded well to intravenous immunoglobulin replacement alone. Our patient had hepatomegaly but no liver or skin disease. HSCT in our patient has not been performed until now because we did not have an accurate molecular diagnosis, so we treated him with a regular IVIG substitution dose of 400 mg/6–4 weeks, since his 9½ years of age. The adherence to the treatment has often been poor, and he has signs of chronic pulmonary damage. He does not attend school, does not cooperate, and spirometry cannot be performed, which make clinical management challenging.

The report of this patient adds to the current clinical and genetic knowledge on ZIP7 deficiency in humans (Table 1). Early recognition and diagnosis of this condition are pivotal for improved outcomes and prevention of complications like lung tissue damage developed over years in this patient. Unfortunately, many patients with PID in ECE still remain without molecular diagnosis. Therefore, collaborative programs with more advanced centers are critically important especially in countries with lower socioeconomic condition and limited resources for molecular diagnostics. Such a program has been established by the JP physician education and clinical research collaboration network in 2004 (www.thejpnetwork.com). The JP provides help for early genetic diagnosis, prenatal genetic testing, treatment, and family counseling of known and even very recently described IIEs like ZIP7 deficiency (Table 2). Supported primarily by educational grants from the European Society for Immunodeficiency (ESID), the Jeffrey Modell Foundation, and a few pharmaceutical companies, the JP coordinated by the Foundation for Children with Immunodeficiencies is now extended to 32 countries in ECE, Asia, and Egypt. The total number of awareness and educational meetings was 344 between 2004 and 2021 and the number of JP meetings per year increased from 5–6 in the first years to 63 in 2021. In 2002, the number of PID patients registered by the ESID registry was less than 10 in most ECE countries (Lennart Hammarström, personal communication). In contrast, a recent survey suggested that the number of PID patients in 30 JP member countries exceeded 24 thousand by the end of 2021 (submitted). The JP meeting also promotes the organization of local PID professional working groups and patient groups, national PID registry, and establishing contact with institutional and governmental health care leadership.

The JP center at the Department of Infectious Diseases and Pediatric Immunology at the University of Debrecen provided molecular genetic service for patients from ECE countries, between 2004 and 2015, free of charge. From 2016, the JP genetic diagnostics program was continued at the Semmelweis University and the Rockefeller University. Altogether, genetic analysis in these three institutions was performed on 316 samples submitted from patients from 15 JP countries (Table 2). Part of the results of these studies has been published before. Taken together, these data suggest that the contribution of the JP to better care of patients and the advancement of clinical research in the field of PID is outstanding and unique in Eurasia over the past two decades.
AUTHOR CONTRIBUTIONS
Melinda Erdős involved in performing bioinformatics analysis and writing the initial draft. Kristina Mironksa involved in conducting clinical research and patient care, and editing the initial draft. Lidia Kareva involved in conducting clinical research and patient care, and data collection. Katarina Stavric involved in conducting clinical research and patient care, and data collection. Arijeta Hasani involved in conducting clinical research and patient care, and data collection. Árpád Lányi involved in conducting targeted gene sequencing. Judit Kállai involved in conducting targeted gene sequencing. László Maródi involved in the formulation of research goals and writing the final draft. All authors reviewed the manuscript.

KEYWORDS
agammaglobulinemia, B cell deficiency, J Project, SLC39A7 mutation, zinc transporter proteins

ACKNOWLEDGEMENTS
We thank the mother of the patient for helpful collaboration. We thank J-L Casanova and B Boisson for helpful discussion. We also thank J-L Casanova for his long-term support of the J Project, in particular, his generous help to allow us in his Laboratory at the Rockefeller University to search for genetic variants in samples of patients from JP countries. This research was supported by the J Project and the Foundation for Children with Immunodeficiencies, and from the European Society for Immunodeficiencies to ME.

CONFLICT OF INTEREST
The authors declare that they have no competing financial interests.

DATA AVAILABILITY STATEMENT
The data that support the findings and the materials used in this study are available on request. The data are not publicly available due to ethical restrictions.

PEER REVIEW
The peer review history for this article is available at https://publon.com/publon/10.1111/pai.13805.

REFERENCES
1. Anzilotti C, Swan DJ, Boisson B, et al. An essential role for the Zn \(\text{Zn}^2+\) transporter ZIP7 in B cell development. Nat Immunol. 2019;20:350-361.
2. Kambe T, Hashimoto A, Fujimoto S. Current understanding of ZIP and ZnT zinc transporters in human health and diseases. Cell Mol Life Sci. 2014;71:3281-3295.
3. Erdős M, Lányi Á, Balázs G, Casanova JL, Boisson B, Maródi L. Inherited TOP2B mutation: possible confirmation of mutational hotspots in the TOPRIM domain. J Clin Immunol. 2021;41:817-819.
4. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2020;40:24-64.
5. Belkadi A, Pedergnana V, Cobat A, et al. Whole-exom sequencing to analyze population structure, parental inbreeding, and familial linkage. Proc Nat Acad Sci USA. 2016;113:6713-6718.
6. Cardenas-Morales M, Hernandes-Trujillo VP. Agammaglobulinemia: from X-linked to Autosomal forms of disease. Clin Rev Allergy Immunol. 2021. 10.1007/s12016-021-08870-5
7. Maródi L. and the J Project Study Group. Fifteen Years of the J Project. J Clin Immunol. 2019;39:636-639.
8. Tuzankina I, Bolkov M, Nabieva U, Lázár I, Maródi L. The J Daughter Siberia Project. J Clin Immunol. 2021;41:262-265.
9. Maródi L. and the J Project Study Group. The 10th anniversary of World Primary Immunodeficiency Week: A J Project celebration. Eur J Immunol. 2021;51:2364-2366.
10. Pac M, Casanova JL, Reisi I, Maródi L. Advances in primary immunodeficiency in Central-Eastern Europe. Front Immunol. 2021;12:667727.
11. Maródi L. and the J Project Study Group. A rose amongst the thorns: the mission of the J Project in a conflictual world. J Clin Immunol. 2022;42(accepted).
12. Erdős M, Uzvölgyi E, Nemes Z, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.
13. Tóth B, Volokha A, Mihas A, et al. Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: a cohort study. Mol Immunol. 2009;46:2140-2146.

CORRESPONDENCE
Melinda Erdős or László Maródi, Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
Email: Erdos.Melinda@med.semmelweis-univ.hu (ME) or Marodi.Laszlo@med.semmelweis-univ.hu (LM)
Editor: Fabio Candotti

ORCID
László Maródi https://orcid.org/0000-0002-9692-3402
14. Maródi L, Casanova JL. Primary immunodeficiency diseases: The J Project. *Lancet*. 2009;373:2179-2181.
15. Gulácsy V, Freiberger T, Shcherbina A, et al. Genetic characteristics of eighty-seven patients with the Wiskott-Aldrich syndrome. *Mol Immunol*. 2011;48:788-792.
16. Soltész B, Tóth B, Shabashova N, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. *J Med Genet*. 2013;50:567-578.
17. Gulácsy V, Soltész B, Petrescu C, et al. A novel large deletion and single nucleotide insertion in the Wiskott-Aldrich syndrome protein gene. *Eur J Haematol*. 2015;95:93-98.
18. Erdős M, Jakobicz E, Soltész B, Tóth B, Bata-Csórgó Z, Maródi L. Recurrent, severe aphthous stomatitis and mucosal ulcers as primary manifestations of a novel STAT1 gain-of-function mutation. *Front Immunol*. 2020;11:967.
19. Erdős M, Tsumura M, Kállai J, et al. Novel STAT3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype. *Clin Exp Immunol*. 2021;205:354-362.
20. Erdős M, Kärner J, Ranki A, Kisand K, Maródi L. Persistently increased anti-cytokine antibodies without clinical disease in a boy with APS1 genotype. *J Clin Immunol*. 2022;42:433-436.

**How to cite this article:** Erdős M, Mironzka K, Kareva L, et al. A novel mutation in SLC39A7 identified in a patient with autosomal recessive agammaglobulinemia: The impact of the J Project. *Pediatr Allergy Immunol*. 2022;33:e13805. doi:[10.1111/pai.13805](https://doi.org/10.1111/pai.13805)